Posted by ABMN Staff on May 14th, 2024
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has received a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Four research analysts have...
More of this article »